Plerixafor is a hematopoietic stem cell mobilizer and inhibitor of the CXCR4 chemokine receptor. CXXR4 is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with potent chemotactic activity for lymphocytes.
Because the interaction between SDF-1 and CXCR4 plays an important role in holding
hematopoietic stem cells in the bone marrow, drugs that block the CXCR4 receptor appear to be capable of
"mobilizing" hematopoietic stem cells into the bloodstream.
Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF), is specifically indicated to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin ’s lymphoma (NHL) and multiple myeloma.
Source:centerwatch
Because the interaction between SDF-1 and CXCR4 plays an important role in holding
hematopoietic stem cells in the bone marrow, drugs that block the CXCR4 receptor appear to be capable of
"mobilizing" hematopoietic stem cells into the bloodstream.
Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF), is specifically indicated to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin ’s lymphoma (NHL) and multiple myeloma.
Source:centerwatch
No comments:
Post a Comment